Why Wegovy doesn't seem to be working for you — and what that actually means

Are you actually at a therapeutic dose yet?

This is the question that resolves things most often. The titration schedule for Wegovy starts at 0.25mg weekly and climbs through 0.5mg, 1.0mg, and 1.7mg before reaching the 2.4mg maintenance dose that the clinical trials were built around. Each step takes roughly four weeks. If you are reading this six or eight weeks in, you may simply not be at the dose where semaglutide's effect on appetite becomes noticeable.

Our guide to why semaglutide works explains how the drug works in more detail, but the short version is this: the lower rungs of the schedule exist to give your digestive system time to adjust, not to produce weight loss. Expecting significant change at 0.5mg is like expecting a car to reach motorway speed in first gear.

Most people in the STEP 1 trial (the landmark study published in the New England Journal of Medicine that found an average 15% body-weight reduction over 68 weeks) reached 2.4mg before meaningful loss accumulated. If you are mid-titration, stay the course and track progress over months, not weeks.

Why some people genuinely respond less to semaglutide

Some people do reach 2.4mg, stay there for three or more months, and still find that Wegovy does not work for them the way the trial averages suggest. That is a real phenomenon, not a personal failure. Biology drives a significant part of the variation. Genetics, gut-hormone baseline levels, insulin sensitivity, thyroid function, and other metabolic factors all influence how strongly GLP-1 receptor agonism affects appetite in any given person.

There is also the question of what the medicine is competing against. Highly processed diets, disrupted sleep, high stress, and certain other medicines (including some antidepressants and steroids) can blunt the response. None of this is about willpower. It is physiology.

If you have read about who semaglutide tends not to work for, you will know that the STEP 1 data showed roughly one in ten participants lost less than 5% body weight at 2.4mg, a minority, but a real one. Knowing you might be in that group is useful information, not a dead end.

What a prescriber can actually do about it

This is the decision the page title is really pointing at: once you have identified that progress has stalled, what do you do? The answer depends on a proper clinical assessment. A prescriber can look at whether you have reached the highest tolerated dose, how long you have been there, what your diet and activity context looks like, and whether any other medical factors might explain the plateau.

From April 2026, the MHRA approved a dedicated single-dose 7.2mg Wegovy pen (the highest semaglutide dose currently licensed) which trials suggest produces around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide. That option may be relevant for people who responded partially at 2.4mg but want to push further, subject to clinical review.

If semaglutide is genuinely a poor fit, tirzepatide (Mounjaro) activates two receptor pathways rather than one and has produced stronger average results in head-to-head evidence. That is not an automatic upgrade, it is a clinical conversation. Our clinical team reviews every patient's situation individually before any prescription decision is made.

For context on what private treatment costs across different providers, the Wegovy pricing page sets out how costs vary and what any legitimate price should include. Worth reading before making a switch decision based partly on cost.

Practical things that make a real difference alongside the medicine

Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity, that framing in the licence is not a footnote. In the STEP 1 trial, all participants received structured lifestyle support. The medicine reduces appetite; it cannot substitute for the eating pattern changes that appetite reduction is meant to make easier.

A few things that come up repeatedly: protein intake often drops when appetite falls, which accelerates muscle loss alongside fat loss and can slow the metabolism further. Hydration matters more than people expect. And resistance activity (even modest amounts) helps preserve lean mass through the weight-loss phase. The NHS semaglutide guidance covers what to eat and what to watch for in clear, practical terms.

If you have a specific concern about how your treatment is going, our support team is available seven days a week. And if you have not yet started but are weighing up whether Wegovy is right for you, understanding why Wegovy may not have worked is a useful starting point before checking eligibility with a real prescriber, one conversation replaces a lot of guesswork. Check your eligibility through a free consultation with our clinical team.